{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:27:55Z","timestamp":1793399275870,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The study aimed to assess how many adult patients with juvenile idiopathic arthritis (JIA) treated with biologics fulfill classification criteria for adult rheumatic diseases and to evaluate the course of JIA in adulthood. 138 patients with JIA over 18\u00a0years old treated with biologics were included in a cross-sectional observative study. Among 138 adult patients with JIA treated with biologics, 81 patients remained with JIA diagnosis. 57 patients were rediagnosed. 31 patients met the criteria for spondyloarthropathy, among them 18 patients for ankylosing spondylitis, 10 patients for psoriatic arthritis, and 3 patients for non-radiographic axial spondyloarthritis. Rheumatoid arthritis was diagnosed in 24 patients and adults\u2019 Still disease in 2 patients. 84 patients of all adults with JIA received one biologic agent, 40 received two biologic agents, and 14 received three or more biologic therapies. 10 patients received biologic agents out of recommendations for JIA. Of the adult JIA patients treated with biologics, 41% met the classification criteria for adult inflammatory diseases. Spondyloarthropathy and rheumatoid arthritis were most commonly diagnosed. Nearly 40% of adult JIA patients required at least one modification of biological treatment. Therefore, it is worth considering a revision of JIA to adult-onset inflammatory disease entities, as it broadens the spectrum of disease-modifying drugs.<\/jats:p>","DOI":"10.1007\/s00296-023-05293-7","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T19:02:36Z","timestamp":1677697356000},"page":"1307-1311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Revising diagnosis of juvenile idiopathic arthritis in adults: a single-center retrospective study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2198-8225","authenticated-orcid":false,"given":"Anna","family":"Felis-Giemza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8301-105X","authenticated-orcid":false,"given":"Kornelia","family":"Chmurzy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9718-0543","authenticated-orcid":false,"given":"Beata","family":"Ko\u0142odziejczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3771-9356","authenticated-orcid":false,"given":"Agnieszka","family":"Gazda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"5293_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390\u2013392","journal-title":"J Rheumatol"},{"key":"5293_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/acr.23870","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T et al (2019) 2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res 71:717\u2013734. https:\/\/doi.org\/10.1002\/acr.23870","journal-title":"Arthritis Care Res"},{"key":"5293_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/rheumatology\/kev398","volume":"55","author":"AF Mour\u00e3o","year":"2016","unstructured":"Mour\u00e3o AF, Santos MJ, Melo Gomes JA et al (2016) Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt. Rheumatology 55:697\u2013703. https:\/\/doi.org\/10.1093\/rheumatology\/kev398","journal-title":"Rheumatology"},{"key":"5293_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4081\/reumatismo.2013.682","volume":"65","author":"M Romano","year":"2014","unstructured":"Romano M, Pontikaki I, Gattinara M et al (2014) Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients. Reumatismo 65:278\u2013285. https:\/\/doi.org\/10.4081\/reumatismo.2013.682","journal-title":"Reumatismo"},{"key":"5293_CR5","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1002\/art.22709","volume":"56","author":"RK Saurenmann","year":"2007","unstructured":"Saurenmann RK, Rose JB, Tyrrell P et al (2007) Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum 56:1974\u20131984. https:\/\/doi.org\/10.1002\/art.22709","journal-title":"Arthritis Rheum"},{"key":"5293_CR6","doi-asserted-by":"publisher","DOI":"10.21802\/acm.2017.1.5","author":"M Dzhus","year":"2017","unstructured":"Dzhus M (2017) Juvenile idiopathic arthritis in adults: long-term observation of ukrainian patients. Arch Clin Med. https:\/\/doi.org\/10.21802\/acm.2017.1.5","journal-title":"Arch Clin Med"},{"key":"5293_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3889\/oamjms.2014.010","volume":"2","author":"Z \u017buber","year":"2014","unstructured":"\u017buber Z, Kania U, Kr\u00f3l-Zdechlikiewicz A et al (2014) Analysis of clinical symptoms and laboratory profiles in children with juvenile idiopathic arthritis in Malopolska region (Poland) in the years 2007\u20132010. OA Maced J Med Sci. 2:56\u201361","journal-title":"OA Maced J Med Sci."},{"key":"5293_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12969-019-0363-0","volume":"17","author":"YJ Shih","year":"2019","unstructured":"Shih YJ, Yang YH, Lin CY et al (2019) Enthesitis-related arthritis is the most common category of juvenile idiopathic arthritis in Taiwan and presents persistent active disease. Pediatr Rheumatol Online J 17:58. https:\/\/doi.org\/10.1186\/s12969-019-0363-0","journal-title":"Pediatr Rheumatol Online J"},{"key":"5293_CR9","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/rheumatology\/ket248","volume":"52","author":"F McErlane","year":"2013","unstructured":"McErlane F, Foster HE, Davies R et al (2013) Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 52:1905\u20131913. https:\/\/doi.org\/10.1093\/rheumatology\/ket248","journal-title":"Rheumatology"},{"key":"5293_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000304","author":"F Oliveira-Ramos","year":"2016","unstructured":"Oliveira-Ramos F, Eus\u00e9bio M, Martins FM et al (2016) Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2016-000304","journal-title":"RMD Open"},{"key":"5293_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5114\/reum.2015.53133","volume":"53","author":"Z \u017buber","year":"2015","unstructured":"\u017buber Z, Turowska-Heydel D, Sobczyk M, Chudek J (2015) Original paper. Prevalence of HLA-B27 antigen in patients with juvenile idiopathic arthritis. Reumatologia 53:125\u2013130. https:\/\/doi.org\/10.5114\/reum.2015.53133","journal-title":"Reumatologia"},{"key":"5293_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13075-017-1297-x","volume":"19","author":"S Gmuca","year":"2017","unstructured":"Gmuca S, Xiao R, Brandon TG et al (2017) Multicenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approaches. Arthritis Res Ther 19:84. https:\/\/doi.org\/10.1186\/s13075-017-1297-x","journal-title":"Arthritis Res Ther"},{"key":"5293_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/OARRR.S163677","volume":"11","author":"RR Mistry","year":"2019","unstructured":"Mistry RR, Patro P, Agarwal V et al (2019) Enthesitis-related arthritis: current perspectives. Open Access Rheumatol 11:19\u201331. https:\/\/doi.org\/10.2147\/OARRR.S163677","journal-title":"Open Access Rheumatol"},{"key":"5293_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.40350","volume":"70","author":"PA Nigrovic","year":"2018","unstructured":"Nigrovic PA, Raychaudhuri S, Thompson SD (2018) Review: genetics and the classification of arthritis in adults and children. Arthritis Rheumatol 70:7\u201317. https:\/\/doi.org\/10.1002\/art.40350","journal-title":"Arthritis Rheumatol"},{"key":"5293_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/RHU.0000000000000819","volume":"25","author":"DM Feger","year":"2019","unstructured":"Feger DM, Longson N, Dodanwala H et al (2019) Comparison of adults with polyarticular juvenile idiopathic arthritis to adults with rheumatoid arthritis: a cross-sectional analysis of clinical features and medication use. J Clin Rheumatol 25:163\u2013170. https:\/\/doi.org\/10.1097\/RHU.0000000000000819","journal-title":"J Clin Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05293-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-023-05293-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05293-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T15:25:55Z","timestamp":1684164355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-023-05293-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["5293"],"URL":"https:\/\/doi.org\/10.1007\/s00296-023-05293-7","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"assertion":[{"value":"11 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}